Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADEP2 is a synthetic acyl-depsipeptide antibiotic that functions as a high-affinity **inhibitor of bacterial ClpP proteases**, specifically **Clp2 protease** in *Mycobacterium tuberculosis* and Gram-positive bacteria. ADEP2 acts by binding to and dysregulating the ClpP protease complex, leading to uncontrolled protein degradation and bacterial cell death. It has shown potent *in vitro* and *in vivo* antibacterial activity, particularly against Gram-positive bacteria such as staphylococci and streptococci. ADEP2 is mainly a research tool and not approved for clinical use[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADEP2.